Fragile X syndrome (FXS/FXTAS/FXPOI). CGG expansions in the FMR1 gene

Fragile X syndrome occurs in individuals with a complete mutation of the FMR1 gene or another loss-of-function variant and it is almost always characterized in affected males by developmental delay and intellectual disability along with a variety of behavioral problems (autism spectrum disorder is present in 50%-70%). Affected males may have characteristic craniofacial features and medical problems including hypotonia, gastroesophageal reflux, strabismus, seizures, sleep disorders, joint laxity, flat feet, scoliosis, and recurrent otitis media. Adults may have mitral valve prolapse or aortic root dilatation.

1/2,400 to 1/6,000 (ORPHA:908).

Service is recommended to rule out Fragile X syndrome since >99% of affected individuals have an expansion in the 5′ UTR region of CGG trinucleotides (more than 200 repeats), detectable by this service.

The benefits derived from a genetic diagnosis in this context are especially aimed at closing the diagnosis and family genetic counseling.

Service indicated when considering the diagnosis of Fragile X syndrome when evaluating a patient with intellectual disabilities.

Request study Informed consent
Steps to follow
Steps to follow

How to order

1. Download & fill out

Please cover as many fields as possible in both documents

2. Sample collection

Three sample types: saliva, peripheral blood or genomic DNA

3. Pack the sample

Please pack the sample in a way to prevent leakage

4. Send the sample & the request

Please schedule the delivery for Monday–Friday: 8am – 5pm

5. Result: the report

Via: e-mail and/or through the customer portal

Ask for information
Solicita información de

Fragile X syndrome (FXS/FXTAS/FXPOI). CGG expansions in the FMR1 gene

"*" indicates required fields

Consentimiento*
This field is for validation purposes and should be left unchanged.
Technique: Fragment Analysis

Turnaround time (TAT): 20 days

Ref. S-202008723

Fragile X syndrome (FXS/FXTAS/FXPOI). CGG expansions in the FMR1 gene: View panel
  • FMR1

Priority Genes : Genes where there is sufficient evidence (clinical and functional) to consider them associated with the disease; they are included in the clinical practice guidelines.
Secondary Genes: Genes related to the disease, but with a lower level of evidence or that constitute sporadic cases.
* Candidate Genes: Not enough evidence in humans, but potentially associated with the disease.

References

  1. Hunter JE, Berry-Kravis E, Hipp H, et al. FMR1 Disorders. 1998 Jun 16 [Updated 2019 Nov 21]. In: Adam MP, Mirzaa GM, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1384/